A Phase III, Randomised, Double-blind, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Against Placebo in Subjects With Iron Deficiency Anaemia and Who Are Intol-erant or Unresponsive to Oral Iron Therapy
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 主要终点
- Proportion of subjects with an Hb increase of ≥ 2 g/dL from baseline at any time from week 1 to week 5
研究概览
简要总结
The primary objective of the study is to evaluate and compare the effect of iron isomaltoside 1000 to placebo in its ability to increase haemoglobin (Hb) in subjects with IDA when oral iron preparations are ineffective or cannot be used.
详细描述
IDA is highly prevalent in subjects and can have a substantial medical and quality of life (QoL) burden on the subjects and the treatment of these subjects includes replenishing lost iron. Oral iron administration is often used in the clinical practice at many clinics; however, oral iron may not be tolerated by all subjects. Hence, there is a need for an alternative iron treatment in subjects, who do not tolerate oral iron.
This study is planned to compare the efficacy and safety of iron isomaltoside 1000 with placebo in subjects with IDA and who are intolerant or unresponsive to oral iron therapy..
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men or women ≥ 18 years having IDA caused by different aetiologies* such as ab-normal uterine bleeding, gastrointestinal diseases (e.g. inflammatory bowel disease), cancer, preoperative anaemia (e.g. orthopaedic surgery), and other conditions leading to IDA and with a documented history of intolerance or unresponsiveness to oral iron therapy** for at least one month*** prior to study enrolment
- •Hb < 11 g/dL
- •TSAT < 20 %
- •S-ferritin < 100 ng/mL
- •Willingness to participate and signing the informed consent form (ICF)
排除标准
- •Hb < 6 g/dL
- •Anaemia predominantly caused by factors other than IDA (e.g. anaemia with untreat-ed vitamin B12 or folate deficiency, haemolytic anaemia)
- •Iron overload or disturbances in utilisation of iron (e.g. haemochromatosis and hae-mosiderosis)
- •Decompensated liver cirrhosis or active hepatitis (ALAT > 3 times upper limit of normal)
- •Active acute or chronic infections (assessed by clinical judgement supplied with white blood cells (WBC) and C-reactive protein (CRP))
- •Body weight < 50 kg
- •Pregnant or nursing women. In order to avoid pregnancy, women of childbearing po-tential have to use adequate contraception (e.g. intrauterine devices, hormonal contra-ceptives, or double barrier method) during the whole study period and 7 days after the last dosing
- •History of multiple allergies
- •Known hypersensitivity to parenteral iron or any excipients in the investigational drug products
- •Erythropoietin treatment within 8 weeks prior to the screening visit
- •Other intravenous (IV) iron treatment or blood transfusion within 4 weeks prior to the screening visit
- •Participation in any other interventional clinical study within 3 months prior to the screening
- •Any other medical condition that, in the opinion of Investigator, may cause the subject to be unsuitable for the completion of the study or place the subject at potential risk from being in the study, e.g. uncontrolled hypertension, unstable ischemic heart disease, or uncontrolled diabetes mellitus
研究组 & 干预措施
Iron isomaltoside 1000
Iron isomaltoside 1000. Dose: 1000 mg, 1500 mg or 2000 mg
干预措施: Iron isomaltoside 1000 (Drug)
Placebo (NaCl 0,9%)
Sodium Chloride. Dose: 100 ml or 5 ml
干预措施: Natrium Chloride 0,9% (Drug)
结局指标
主要结局
Proportion of subjects with an Hb increase of ≥ 2 g/dL from baseline at any time from week 1 to week 5
时间窗: Week 1 to 5
次要结局
- Time to Hb ≥ 2 g/dL(Week 1 to 5)